Top Markets
#1 PumpMeme PumpMeme +1,053.55%
#2 ALEO ALEO +71.52%
#3 Siren Siren +31.74%
#4 World Mobile Token World Mobile Token +30.46%
#5 peaq peaq +27.38%
#6 Quant Quant +27.34%
#7 Ondo Ondo +26.56%
#8 CZ'S Dog CZ'S Dog +26.20%
#9 Wrapped XPL Wrapped XPL +24.78%
#10 Unit Plasma Unit Plasma +24.68%
Coin of the day
PumpMeme PumpMeme
Settings
Language
ENGLISH
Currency
USD
Theme
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
Rank in Stocks #31262
Noxopharm Limited is an Australian drug development company with an... Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers. Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors. The LuPIN program explores a combined therapy of Veyonda and 177Lu-PSMA-617 for advanced prostate cancer. The IONIC program combines Veyonda with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, targeting various solid tumor types. Its Chemotherapy Enhancement Program (CEP) integrates Veyonda with carboplatin for patients suffering from refractory solid tumors in areas such as the breast, head and neck, lung, prostate, and ovaries. Furthermore, the NOXCOVID Program is conducting a dose escalation and expansion study of NOX66 for the treatment of COVID-19 infection. The company is also investigating potential treatments for pancreatic cancer and glioblastoma. Noxopharm collaborates with the Hudson Institute of Medical Research and The Australian National University on the research and development of therapeutic drugs for inflammatory disorders. Incorporated in 2015, the company's operations are based in Chatswood, Australia.
Share Price
$0.04443294
Market Cap
$13.65M
Change (1 day)
0.00%
Change (1 year)
-32.53%
Country
AU
Trade Noxopharm Limited (NOX)

Category

Healthcare
Revenue for Noxopharm Limited (NOX)
Revenue in Jun 2026 TTM: 0.00
According to Noxopharm Limited latest financial reports the company's current revenue (TTM) is 0.00. In 2024 the company made a revenue of $1.60M a decrease compared to the revenue in the year 2023 that was $4.00M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Noxopharm Limited from 2016 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) 0.00 -100.00%
2025 $1.86M 15.87%
2024 $1.60M -59.98%
2023 $4.00M 6.95%
2022 $3.74M -10.96%
2021 $4.21M -26.42%
2020 $5.71M 116.95%
2019 $2.63M 288.04%
2018 $678.81K 597.95%
2017 $97.26K 0.00%
2016 0.00 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH